Sharyn Baker

Sharyn Baker has made critical contributions to pediatric oncology pharmacology, demonstrating that developmental changes in drug metabolism enzyme expression (ontogeny) create unique pharmacokinetic profiles in children that require specific dose optimization approaches distinct from simple allometric scaling from adult doses. Her research showed that CYP3A4 maturation, UGT enzyme development, and renal function changes in pediatric patients significantly alter anticancer drug exposure. She established pharmacokinetic guidelines for dosing targeted therapies in pediatric cancer patients. Her work has improved the safety and efficacy of cancer treatment in children through age-appropriate pharmacological approaches.